ENDRA Life Sciences (NDRA) Common Equity (2016 - 2021)
Historic Common Equity for ENDRA Life Sciences (NDRA) over the last 6 years, with Q3 2021 value amounting to $13.2 million.
- ENDRA Life Sciences' Common Equity rose 29448.69% to $13.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $13.2 million, marking a year-over-year increase of 29448.69%. This contributed to the annual value of $7.2 million for FY2020, which is 5059.48% up from last year.
- Latest data reveals that ENDRA Life Sciences reported Common Equity of $13.2 million as of Q3 2021, which was up 29448.69% from $15.0 million recorded in Q2 2021.
- In the past 5 years, ENDRA Life Sciences' Common Equity ranged from a high of $17.9 million in Q1 2021 and a low of -$1.4 million during Q1 2017
- Moreover, its 5-year median value for Common Equity was $3.8 million (2019), whereas its average is $5.3 million.
- In the last 5 years, ENDRA Life Sciences' Common Equity plummeted by 10638.43% in 2018 and then soared by 143446.68% in 2021.
- ENDRA Life Sciences' Common Equity (Quarter) stood at $5.3 million in 2017, then rose by 18.44% to $6.2 million in 2018, then dropped by 23.81% to $4.8 million in 2019, then skyrocketed by 50.59% to $7.2 million in 2020, then skyrocketed by 83.51% to $13.2 million in 2021.
- Its last three reported values are $13.2 million in Q3 2021, $15.0 million for Q2 2021, and $17.9 million during Q1 2021.